HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $50
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $55 to $50.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $55 to $50.